Doximity earnings missed by $0.02, revenue topped estimates

Doximity reported Q1 EPS of $0.26, missing the $0.28 analyst estimate by $0.02, while revenue came in slightly above consensus at $145.4M versus $144.07M expected. The company guided FY2027 revenue to $664M-$676M, above the $643.6M consensus, but the earnings miss and weak share performance frame the update as mixed. The stock closed at $23.39 and is down 6.51% over the past 3 months and 60.40% over the past 12 months.

Analysis

The key takeaway is not the modest earnings miss; it’s that the market is still punishing DOCS as a duration-sensitive healthcare SaaS name despite management resetting revenue expectations above the Street. That combination usually matters more for the next 2-3 quarters than the quarter’s EPS print, because the stock has already de-rated into a “prove-it” multiple where guidance stability can drive outsized rerating if selling pressure exhausts. The current setup looks less like a fundamental break and more like a positioning washout with a high short-interest style overhang.

The second-order issue is that Doximity’s business is tied to healthcare ad budgets and physician workflow spend, both of which are among the first digital line items to get deferred in a tighter macro environment. If peers begin to talk more cautiously about customer budgets, DOCS could underperform even on clean execution because investors will extrapolate weaker booking durability across the ad-tech/healthcare software complex. Conversely, if management can show that the revenue guide is being driven by better monetization rather than one-off demand, the market may re-rate it quickly because the selloff has likely compressed expectations too far.

The broader signal from the revisions data is that analysts have already walked numbers down, so the bar for incremental downside is lower than the bar for upside surprise. That creates a setup where the stock can stay weak for days, but the more interesting risk/reward is over months: any evidence of stabilized revisions or improved take-rate could force a squeeze. The contrarian view is that this may be a classic “good company, bad tape” dislocation rather than a secular deterioration, especially if the company’s financial quality remains intact and revenue visibility is better than the market is pricing.

Key Decisions for Investors

• Initiate a small starter long in DOCS over 1-2 weeks only after post-earnings selling slows; use a tight stop if the stock loses recent lows, because the near-term tape is still negative even if fundamentals are intact.
• For a cleaner expression, pair long DOCS / short a higher-beta healthcare SaaS peer basket over 1-3 months; thesis is mean reversion in a name that has already derated harder than fundamentals justify.
• If options liquidity is sufficient, buy 2-3 month call spreads on DOCS to express a rebound without paying full implied volatility; target a 1.5-2.0x payoff if the market re-prices guidance credibility.
• Avoid adding until management can demonstrate that FY 2027 guide is not being cushioned by one-time assumptions; if the next print confirms recurring monetization, the stock could rerate sharply, but absent that, capital should be kept light.
• Set a catalyst watch over the next 30-60 days for any peer commentary on healthcare marketing budgets; a stabilization in sector spending would be the fastest path to upside re-rating.